• 제목/요약/키워드: critical cancer

검색결과 804건 처리시간 0.022초

CI보험중 '중대한 암'(Critical cancer)의 정의에 관한 Medical Underwriting의 제한적요소에 관한 고찰 (The limitation of Medical Underwriting on the definition of Critical cancer in Critical Insurance)

  • 정헌종
    • 보험의학회지
    • /
    • 제25권
    • /
    • pp.63-77
    • /
    • 2006
  • 국내 CI보험에서 정의한 '중대한 암'이란 용어는 의학적인 '암'의 정의보다는 다소 보험적인 의미를 가진 암으로 정의되고 있다. 따라서 의학적으로 정의된 암과 다른 보험적인 의미에서 암을 정의함에 따라 의료인이나 일반인이 생각하고 있는 암의 정의와 다른 개념의 차이로 보험사와 계약자간의 Medical Underwriting에서 많은 문제점이 있을 것으로 판단되었다. 이처럼 CI보험에서 정의한 '중대한 암'의 정의가 의학적 정의된 '암'과의 차이로 보험사와 계약자간의 분쟁의 소지가 될 수 있는 '중대한 암'의 Medical Underwriting의 제한적 요소로는 제I항의 정의에서 1) '암'과 '중대한 암'의 정의에 차이에 따른 보험사, 계약자, 의료인의 입장에서 본 제한적 요소 2) "악성신생물분류표"가 가지는 의미에 관한 제한적 요소 3) '중대한 암'과 '고액치료비 암'의 용어에 대한 제한적 요소를 고찰하였다. 제II항의 정의에서는 1) 암성의 변화에 따른 제한적요소 2)악성병변 부위가 국한된 경우 병리조직검사에서 악성으로 나타나지 않은 경우의 제한적 요소 3) 병원간 병리조직 검사결과의 차이에 따른 제한적 요소에 관해 고찰하였다. 제III항의 정의에서는 1) 하위조항이 상위조항에 위배되는 경우의 제한적 요소 2) 임상적 악성에 대한 제한적 요소를 고찰하였다. 그 외에도 '중대한 암'에서 제외되는 암으로 1)악성흑색종에서 침범정도가 낮은 경우 2) 초기전립샘 암 3) HIV에 관련된 악성종양 4) 악성흑색종을 제외한 모든 피부암들에 대한 제한적인 요소 5) 양성종양,전암병소,상피내암,경계성종양 등이 임상적으로 '중대한 암'으로 인정되는 경우와 진단서 작성에서의 제한적 요소를 고찰하여 '중대한 암'에 대한 Medical Underwriting의 문제점을 파악하였다.

  • PDF

암전문병원 간호사의 비판적 사고성향, 임상 의사결정능력, 직무만족도에 관한 연구 (Relationship between Critical Thinking Disposition, Clinical Decision Making and Job Satisfaction of Cancer Center Nurses)

  • 정삼출;정덕유
    • 간호행정학회지
    • /
    • 제17권4호
    • /
    • pp.443-450
    • /
    • 2011
  • Purpose: This study was a descriptive correlation study to increase understanding of, and relationships among critical thinking disposition, clinical decision making and job satisfaction of cancer center nurses. Method: The participants in this study were 150 nurses working in one cancer center located in Gyeonggi Province. The statistic program, SPSS WIN17.0 was used for data analysis and data were analyzed using t-test, ANOVA, and Pearson correlation. Results: The critical thinking disposition of the participants showed statistically significant differences according to areas of practice (F=4.426, p=.005), and current position (F=9.346, p=.000). For clinical decision making of the participants, statistically significant differences were found according to current position (F=10.667, p=.000). Furthermore, for job satisfaction, there were statistically significant differences according to income (F=6.779, p=.002), length of career (F=2.701, p=.033) and current position (F=5.423, p=.005). There were significant positive correlations for critical thinking disposition with clinical decision making, and with job satisfaction. Conclusions: The results of the study indicate that to improve clinical decision making and job satisfaction of cancer center nurses, it is necessary to increase critical thinking disposition. To make this change, appropriate programs are needed to increase critical thinking and clinical decision making of general cancer center nurses.

'표준치료를 받은 폐암 환자의 한방병원 입원 임상경로' 개발 및 적용 (Developed and Implemented a Clinical Pathway for Lung Cancer Patients Admitted to Korean Medicine Hospital after Standard Treatment)

  • 고금영;박소정;김동현;하기태;유화승;윤성훈;최준용
    • 동의생리병리학회지
    • /
    • 제37권6호
    • /
    • pp.178-184
    • /
    • 2023
  • The objective of this study was to develop a critical pathway of integrative medicine to improve the quality of life of lung cancer patients who received standard western medicine treatments. A total of 10 medical professionals, including western and Korean medicine doctors, and nurses participated in a validation survey and revised clinical pathway. Then we applied the critical pathway to 11 lung cancer patients who admitted at Korean medicine hospital and evaluated quality of life at the beginning and discharge of admission using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire(EORTC QLQ). More than 80% of the respondents gave a score of 3 (appropriate) or more for all items in the validation survey and we modified the clinical pathway by adding 'bed rest'to the activity item. When applying the revised critical pathway to 11 lung cancer patients, the score of 'Nausea and vomiting', 'Insomnia' in EORTC QLQ-30 and 'chest pain'in EORTC LC-13 showed statistically significant improvements in the before-and-after admission comparision. The application of revised inpatient critical pathway of integrative medicine for lung cancer showed improvement in some symptoms. Development of more critical pathway in various clinical setting and larger scaled application studies of critical pathway are needed.

Spontaneous Regression of Non-Small Cell Lung Cancer in a Patient with Idiopathic Pulmonary Fibrosis: A Case Report

  • Hwang, Eu Dong;Kim, Young Jae;Leem, Ah Young;Ji, Ah-Young;Choi, Younjeong;Jung, Ji Ye;Kim, Se Kyu;Chang, Joon;Park, Ji Hye;Park, Seon Cheol
    • Tuberculosis and Respiratory Diseases
    • /
    • 제75권5호
    • /
    • pp.214-217
    • /
    • 2013
  • Treatment of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) is difficult because the mortality rate after surgery or chemotherapy is high for these patients. Spontaneous regression of cancer is rare, especially in lung cancer. A 62-year-old man, previously diagnosed with IPF, presented with stage IIIC (T2N3M0) non-small cell lung cancer. About 4 months later, spontaneous regression of the primary tumor was observed without treatment. To the best of our knowledge, this is the first report of spontaneous regression of lung cancer in a patient with IPF.

비소세포성 폐암 환자의 항암화학요법을 위한 Critical Pathway개발과 적용효과 (Development of a Critical Pathway for the Chemotherapy of Non-small Cell Lung Cancer Patients and Its Effects)

  • 최자윤;장금성;최은영
    • 간호행정학회지
    • /
    • 제8권1호
    • /
    • pp.85-95
    • /
    • 2002
  • The purpose of this study was to develope a critical pathway for the chemotherapy of non-small cell lung cancer patients and to identify its effects after implementation. Critical pathway was developed through 5 steps including content and clinical validity tests with collaborative efforts of nurses, clinicians, and other allied healthcare professionals with the aim of improving the quality of patient care, while minimizing cost to the patients. This paper was described an evaluation of the impact of a developed critical pathway on complication rate, length of stay, costs, the interval of treatment and patient satisfaction by nonequivalent control group posttest-only non-synchronized research design.Results were compared between the two groups of patients. There were no significant differences in demographic variables and the occurrence of bone marrow suppression between experimental group and control group(t=-0.01, p=0.992). There were statistically significant decreases in the average length of stay(t=-10.45, p=0.000), in the average cost(t=-2.988, p=0.004), and in the interval of treatment(t=-6.75, p=0.000) after implementation of the critical pathway compared to control group. Also, there was a statistically significant improvement of the patient satisfaction after implementation of the critical pathway compared to control group(t=4.57, p=0.000). This paper concludes that critical pathway in chemotherapy for lung cancer, implemented in the context of an general hospital, is the useful tool to shorten the hospital stay, reduce treatment costs, and improve the quality of life in cancer patients. Further study needs to be conducted to identify other clinical outcomes including job satisfaction, collaboration among health professionals and potential for use in education. Also, it is recommended that nurses should revise continuously the developed critical pathway through clinical implementation and maintain their role of patient advocacy through monitoring pathway compliance.

  • PDF

Erlotinib-Related Spontaneous Pneumothorax in Patient with Primary Lung Cancer

  • Nam, Hae-Seong;Lee, Hyeon-Jeong;Kim, Min-Su;Park, Sung-Wook;Jeon, Sang-Hoon;Cho, Jae-Hwa;Kwak, Seung-Min;Lee, Hong-Lyeol;Ryu, Jeong-Seon
    • Tuberculosis and Respiratory Diseases
    • /
    • 제69권6호
    • /
    • pp.465-468
    • /
    • 2010
  • Spontaneous pneumothorax (SPTx) associated with primary lung cancer is quite rare, but has been reported as the initial presentation or a complication of disease progression. Moreover, chemotherapy-related SPTx in primary lung cancer occurs at a very low frequency, accounting for less than 0.05% of all cases. Here, we report the first case of erlotinib-related SPTx in a patient with advanced lung adenocarcinoma in Korea. After 3 cycles of cisplatin-based chemotherapy as first-line therapy, erlotinib was administered as second-line treatment. Asymptomatic SPTx accompanied by a significant decrease in tumor size was observed in the left lung 7 weeks later. The patient received continuous administration of erlotinib, without additional treatment. This case showed that SPTx can occur in patients with primary lung cancer receiving erlotinib, and asymptomatic chemotherapy-related SPTx in primary lung cancer may not require therapeutic intervention.

'항암화학요법을 받은 폐암 환자의 예비 통합의학 임상경로' 개발 및 타당도 평가 (Development and Validity Test on Preliminary Critical Pathway of Integrative Medicine for Lung Cancer Patients Treated with Chemotherapy)

  • 홍미나;심소현;윤성훈;최준용;김윤성
    • 대한한방내과학회지
    • /
    • 제38권6호
    • /
    • pp.917-929
    • /
    • 2017
  • Objectives: The objective of this study was to investigate the validity of the preliminary critical pathway of integrative medicine to improve the quality of life of lung cancer patients who received chemotherapy. Methods: The vertical axis of the preliminary critical pathway of integrated medicine consisted of nine domains: assessment, treatment, activity, consult, diet, medication, Korean medical examination, education, and others. The frame of the horizontal axis was the date from hospitalization to discharge. A total of 105 items in this preliminary critical pathway were validated by an expert group from October 28, 2016 to November 4, 2016. A total of ten experts from two different medical institutions participated in the validity test, using the four-point Content Validity Index (CVI) scale. The items with validity of greater than 80% were considered as significant. Results: The analysis of the content validity of 105 items showed 102 items with greater than 80% agreement. Assessment, treatment, consult, diet, medication, and education showed 100% agreement. Only three items showed a low validity (62.5%). Based on additional comments, the preliminary critical pathway of integrative medicine has been supplemented. Conclusions: This study suggests the possibility of using the integrated medical critical pathway for patients with lung cancer who received chemotherapy.

CHRNA5 rs16969968 Polymorphism Association with Risk of Lung Cancer - Evidence from 17,962 Lung Cancer Cases and 77,216 Control Subjects

  • Xu, Zhi-Wei;Wang, Guan-Nan;Dong, Zhou-Zhou;Li, Tao-Hong;Cao, Chao;Jin, Yu-Hong
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권15호
    • /
    • pp.6685-6690
    • /
    • 2015
  • Background: Genetic studies have shown a possible relationship between the rs16969968 polymorphism in CHRNA5 and the risk of lung cancer. However, the results have been conflicting. Thus we rigorously conducted a meta-analysis to clarify any association. Materials and Methods: A total of 10 case-control studies involving 17,962 lung cancer cases and 77,216 control subjects were analysed. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of the association. Results: We found the CHRNA5 rs16969968 polymorphism to be associated with the risk of lung cancer (AA vs GG: OR=1.60, 95%CI=1.51-1.71). On stratified analysis by smoking status, a statistically significant increased risk was observed in the smoking group (AA vs GG: OR=1.80, 95%CI=1.61-2.01). However, this polymorphism was not associated with lung cancer risk in Asians (AA vs GG: OR=0.95, 95%CI=0.35-2.59), whereas it was linked to increased risk of lung cancer among Caucasians (AA vs GG: OR=1.65, 95%CI=1.55-1.76). Conclusions: Our meta-analysis provided statistical evidence for a strong association between rs16969968 polymorphism and the risk of lung cancer, especially in smokers and Caucasians. Application of this relationship may contribute to identification of individuals at high risk of lung cancer and indicate a chemoprevention target.

Recent Trends of Lung Cancer in Korea

  • Lee, Jae Guk;Kim, Ho Cheol;Choi, Chang-Min
    • Tuberculosis and Respiratory Diseases
    • /
    • 제84권2호
    • /
    • pp.89-95
    • /
    • 2021
  • Lung cancer is one of the leading causes of cancer-related deaths in Korea. Although the smoking rate has decreased over time, the prevalence of lung cancer still remains high. In this study, we reviewed recent trends on the incidence, epidemiology, screening, diagnosis, and treatment of lung cancer in Korea by analyzing data from the national lung cancer registry and recently-published studies. Although approximately 40% of patients with non-small cell lung cancer (NSCLC) were diagnosed as stage IV, the 5-year relative survival rate improved from 11.3% (1993-1995) to 30.2% (2013-2017), possibly due to advances in methods of diagnosis and therapy. In addition, the 2019 implementation of the national lung cancer screening program with low-dose computed tomography may have also contributed to these improvements in survival rates. Recently, molecular diagnosis has become more widely used in the identification of genetic mutations in tissue specimens. Target therapy and immune checkpoint inhibitors have also been successfully used, particularly in cases of advanced NSCLC. In the future, further research on the optimal management of lung cancer remains necessary.